

7 Literaturverzeichnis

1. Cleavage of tetrapeptide-pNA substrates by BIOMOL caspases.
BIOMOL Research News (2000), **9**, 9
2. Abreo, C. B., and Stainer, D. W., A tissue culture assay for diphtheria toxicity testing.
Dev Biol Stand (1986), **64**: 33-37
3. Anderson, D. R., Grillo-Lopez, A., Varns, C., Chambers, K. S., and Hanna, N., Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
Biochem Soc Trans (1997), **25**(2): 705-708
4. Armah, C. N., Mackie, A. R., Roy, C., Price, K., Osbourn, A. E., Bowyer, P., and Ladha, S., The membrane-permeabilizing effect of avenacin A-1 involves the reorganization of bilayer cholesterol.
Biophys J (1999), **76**(1 Pt 1): 281-290
5. Azemar, M., Schmidt, M., Arlt, F., Kennel, P., Brandt, B., Papadimitriou, A., Groner, B., and Wels, W., Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Int J Cancer (2000), **86**(2): 269-275
6. Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V., and Vitetta, E. S., Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.
Proc Natl Acad Sci U S A (1999), **96**(7): 3957-3962
7. Bangham, A. D., Horne, R. W., Glauert, A. M., Dingle, J. T., and Lucy, J. A., Action of saponin on biological cell membranes.
Nature (1962), **196**: 952-955
8. Barbieri, L., Ferreras, J. M., Barraco, A., Ricci, P., and Stirpe, F., Some ribosome-inactivating proteins depurinate ribosomal RNA at multiple sites.
Biochem J (1992), **286** (Pt 1): 1-4
9. Barbieri, L., Valbonesi, P., Govoni, M., Pession, A., and Stirpe, F., Polynucleotide:adenosine glycosidase activity of saporin-L1: effect on various forms of mammalian DNA.
Biochim Biophys Acta (2000), **1480**(1-2): 258-266
10. Barret, A. J., Rawlings, N. D., and Woessner, J. F., Handbook of proteolytic enzymes.
Academic Press, San Diego, USA (1998)
11. Barth, S., Huhn, M., Matthey, B., Schnell, R., Tawadros, S., Schinkothe, T., Lorenzen, J., Diehl, V., and Engert, A., Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
Int J Cancer (2000), **86**(5): 718-724
12. Barth, S., Matthey, B., Huhn, M., Diehl, V., and Engert, A., CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Cytokines Cell Mol Ther (1999), **5**(2): 69-78
13. Barthelemy, I., Martineau, D., Ong, M., Matsunami, R., Ling, N., Benatti, L., Cavallaro, U., Soria, M., and Lappi, D. A., The expression of saporin, a ribosome-inactivating protein from the plant *Saponaria officinalis*, in *Escherichia coli*.
J Biol Chem (1993), **268**(9): 6541-6548
14. Bassi, D. E., Mahloogi, H., Al-Saleem, L., Lopez De Cicco, R., Ridge, J. A., and Klein-Szanto, A. J., Elevated furin expression in aggressive human head and neck tumors and tumor cell lines.
Mol Carcinog (2001), **31**(4): 224-232
15. Bassi, D. E., Mahloogi, H., Lopez De Cicco, R., and Klein-Szanto, A., Increased furin activity enhances the malignant phenotype of human head and neck cancer cells.
Am J Pathol (2003), **162**(2): 439-447
16. Beerens, A. M., Al Hadithy, A. F., Rots, M. G., and Haisma, H. J., Protein transduction domains and their utility in gene therapy.
Curr Gene Ther (2003), **3**(5): 486-494

17. Bell, C. E., and Eisenberg, D., Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. *Biochemistry* (1996), **35**(4): 1137-1149
18. Bolognesi, A., Tazzari, P. L., Legname, G., Olivieri, F., Modena, D., Conte, R., and Stirpe, F., Anti-CD30 immunotoxins with native and recombinant diphtheria toxin. *Cancer Immunol Immunother* (1995), **40**(2): 109-114
19. Brayden, D. J., Controlled release technologies for drug delivery. *Drug Discov Today* (2003), **8**(21): 976-978
20. Bruell, D., Stocker, M., Huhn, M., Redding, N., Kupper, M., Schumacher, P., Paetz, A., Bruns, C. J., Haisma, H. J., Fischer, R., Finnern, R., and Barth, S., The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. *Int J Oncol* (2003), **23**(4): 1179-1186
21. Carter, P., Improving the efficacy of antibody-based cancer therapies. *Nat Rev Cancer* (2001), **1**(2): 118-129
22. Casale, F., Canaparo, R., Serpe, L., Muntoni, E., Pepa, C. D., Costa, M., Mairone, L., Zara, G. P., Fornari, G., and Eandi, M., Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. *Pharmacol Res* (2004), **50**(2): 173-179
23. Cavallaro, U., Nykjaer, A., Nielsen, M., and Soria, M. R., Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins. *Eur J Biochem* (1995), **232**(1): 165-171
24. Cawley, D. B., Herschman, H. R., Gilliland, D. G., and Collier, R. J., Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. *Cell* (1980), **22**(2 Pt 2): 563-570
25. Chan, S. Y., Gordon, A. N., Coleman, R. E., Hall, J. B., Berger, M. S., Sherman, M. L., Eten, C. B., and Finkler, N. J., A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. *Cancer Immunol Immunother* (2003), **52**(4): 243-248
26. Chari, R. V., Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. *Adv Drug Deliv Rev* (1998), **31**(1-2): 89-104
27. Chari, R. V., Jackel, K. A., Bourret, L. A., Derr, S. M., Tadayoni, B. M., Mattocks, K. M., Shah, S. A., Liu, C., Blattler, W. A., and Goldmacher, V. S., Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. *Cancer Res* (1995), **55**(18): 4079-4084
28. Chaudhary, V. K., FitzGerald, D. J., and Pastan, I., A proper amino terminus of diphtheria toxin is important for cytotoxicity. *Biochem Biophys Res Commun* (1991), **180**(2): 545-551
29. Chauhan, S. C., Jain, M., Moore, E. D., Wittel, U. A., Li, J., Gwilt, P. R., Colcher, D., and Batra, S. K., Pharmacokinetics and biodistribution of ¹⁷⁷Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. *Eur J Nucl Med Mol Imaging* (2005), **32**(3): 264-273
30. Cheng, J., Huang, H., Zhang, Z. T., Shapiro, E., Pellicer, A., Sun, T. T., and Wu, X. R., Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. *Cancer Res* (2002), **62**(14): 4157-4163
31. Chinn, P. C., Leonard, J. E., Rosenberg, J., Hanna, N., and Anderson, D. R., Preclinical evaluation of ⁹⁰Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. *Int J Oncol* (1999), **15**(5): 1017-1025
32. Chiron, M. F., Fryling, C. M., and FitzGerald, D., Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. *J Biol Chem* (1997), **272**(50): 31707-31711
33. Chiron, M. F., Fryling, C. M., and FitzGerald, D. J., Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. *J Biol Chem* (1994), **269**(27): 18167-18176

34. Choe, S., Bennett, M. J., Fujii, G., Curmi, P. M., Kantardjieff, K. A., Collier, R. J., and Eisenberg, D., The crystal structure of diphtheria toxin.
Nature (1992), **357**(6375): 216-222
35. Chung, D. W., and Collier, R. J., The mechanism of ADP-ribosylation of elongation factor 2 catalyzed by fragment A from diphtheria toxin.
Biochim Biophys Acta (1977), **483**(2): 248-257
36. Collier, R. J., Effect of diphtheria toxin on protein synthesis: inactivation of one of the transfer factors.
J Mol Biol (1967), **25**(1): 83-98
37. Cosman, D., Cerretti, D. P., Larsen, A., Park, L., March, C., Dower, S., Gillis, S., and Urdal, D., Cloning, sequence and expression of human interleukin-2 receptor.
Nature (1984), **312**(5996): 768-771
38. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I., and Van Cutsem, E., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
N Engl J Med (2004), **351**(4): 337-345
39. Derossi, D., Chassaing, G., and Prochiantz, A., Trojan peptides: the penetratin system for intracellular delivery.
Trends Cell Biol (1998), **8**(2): 84-87
40. Donovan, M. G., Veldman, S. A., and Bodley, J. W., A screening procedure for the intracellular expression of native proteins by *Saccharomyces cerevisiae*: discrimination of diphtheria toxin-resistant mutants.
Yeast (1992), **8**(8): 629-633
41. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cervený, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D., Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Nat Biotechnol (2003), **21**(7): 778-784
42. Drin, G., Cottin, S., Blanc, E., Rees, A. R., and Tamsamani, J., Studies on the internalization mechanism of cationic cell-penetrating peptides.
J Biol Chem (2003), **278**(33): 31192-31201
43. Dumont-Miscopein, A., Lavergne, J. P., Guillot, D., Sontag, B., and Reboud, J. P., Interaction of phosphorylated elongation factor EF-2 with nucleotides and ribosomes.
FEBS Lett (1994), **356**(2-3): 283-286
44. Dumont-Miscopein, A., Lavergne, J. P., and Reboud, J. P., Properties of elongation factor-2 fragments obtained by partial proteolysis.
Biochim Biophys Acta (1995), **1263**(3): 221-227
45. Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H., Mammalian caspases: structure, activation, substrates, and functions during apoptosis.
Annu Rev Biochem (1999), **68**: 383-424
46. Eckenberg, R., Rose, T., Moreau, J. L., Weil, R., Gesbert, F., Dubois, S., Tello, D., Bossus, M., Gras, H., Tartar, A., Bertoglio, J., Chouaib, S., Goldberg, M., Jacques, Y., Alzari, P. M., and Theze, J., The first alpha helix of interleukin (IL)-2 folds as a homotetramer, acts as an agonist of the IL-2 receptor beta chain, and induces lymphokine-activated killer cells.
J Exp Med (2000), **191**(3): 529-540
47. Efstratiou, A., Engler, K. H., Dawes, C. S., and Sesardic, D., Comparison of phenotypic and genotypic methods for detection of diphtheria toxin among isolates of pathogenic corynebacteria.
J Clin Microbiol (1998), **36**(11): 3173-3177
48. Efstratiou, A., Engler, K. H., Mazurova, I. K., Glushkevich, T., Vuopio-Varkila, J., and Popovic, T., Current approaches to the laboratory diagnosis of diphtheria.
J Infect Dis (2000), **181** Suppl 1: S138-145
49. Elek, S. D., The plate virulence test for diphtheria.
J Clin Pathol (1949), **2**(4): 250-258
50. Endo, Y., Mitsui, K., Motizuki, M., and Tsurugi, K., The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins.
J Biol Chem (1987), **262**(12): 5908-5912

51. Endo, Y., and Wool, I. G., The site of action of alpha-sarcin on eukaryotic ribosomes. The sequence at the alpha-sarcin cleavage site in 28 S ribosomal ribonucleic acid.
J Biol Chem (1982), **257**(15): 9054-9060
52. Engert, A., Diehl, V., Schnell, R., Radszuhn, A., Hatwig, M. T., Drillich, S., Schon, G., Bohlen, H., Tesch, H., Hansmann, M. L., Barth, S., Schindler, J., Ghetie, V., Uhr, J., and Vitetta, E., A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
Blood (1997), **89**(2): 403-410
53. Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., Sneige, N., Smith, T. L., and Hortobagyi, G. N., Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
J Clin Oncol (2002), **20**(7): 1800-1808
54. Falnes, P. O., Choe, S., Madshus, I. H., Wilson, B. A., and Olsnes, S., Inhibition of membrane translocation of diphtheria toxin A-fragment by internal disulfide bridges.
J Biol Chem (1994), **269**(11): 8402-8407
55. Falnes, P. O., and Olsnes, S., Cell-mediated reduction and incomplete membrane translocation of diphtheria toxin mutants with internal disulfides in the A fragment.
J Biol Chem (1995), **270**(35): 20787-20793
56. Falnes, P. O., Wesche, J., and Olsnes, S., Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment.
Biochemistry (2001), **40**(14): 4349-4358
57. Ferrara, N., VEGF and the quest for tumour angiogenesis factors.
Nat Rev Cancer (2002), **2**(10): 795-803
58. Ferrara, N., Hillan, K. J., Gerber, H. P., and Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Nat Rev Drug Discov (2004), **3**(5): 391-400
59. Foss, F. M., DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology.
Clin Lymphoma (2000), **1 Suppl 1**: S27-31
60. Francis, G., Kerem, Z., Makkar, H. P., and Becker, K., The biological action of saponins in animal systems: a review.
Br J Nutr (2002), **88**(6): 587-605
61. Frankel, A. D., and Pabo, C. O., Cellular uptake of the tat protein from human immunodeficiency virus.
Cell (1988), **55**(6): 1189-1193
62. Frankel, A. E., Fleming, D. R., Hall, P. D., Powell, B. L., Black, J. H., Leftwich, C., and Gartenhaus, R., A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Clin Cancer Res (2003), **9**(10 Pt 1): 3555-3561
63. Frankel, A. E., Fleming, D. R., Powell, B. L., and Gartenhaus, R., DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
Expert Opin Biol Ther (2003), **3**(1): 179-186
64. Frankel, A. E., Kreitman, R. J., and Sausville, E. A., Targeted toxins.
Clin Cancer Res (2000), **6**(2): 326-334
65. Fuchs, H., Bachran, C., Heisler, I., and Sutherland, M., A closer look at protein transduction domains as a tool in drug delivery.
Current Nanoscience (2005)(2): 117-124
66. Gaffen, S. L., Signaling domains of the interleukin 2 receptor.
Cytokine (2001), **14**(2): 63-77
67. Gill, D. M., Bacterial toxins: a table of lethal amounts.
Microbiol Rev (1982), **46**(1): 86-94
68. Goetzl, E. J., Kong, Y., and Kenney, J. S., Lysophospholipid enhancement of human T cell sensitivity to diphtheria toxin by increased expression of heparin-binding epidermal growth factor.
Proc Assoc Am Physicians (1999), **111**(3): 259-269
69. Goff, B. A., Blake, J., Bamberg, M. P., and Hasan, T., Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model.
Br J Cancer (1996), **74**(8): 1194-1198

70. Gogelein, H., and Huby, A., Interaction of saponin and digitonin with black lipid membranes and lipid monolayers. *Biochim Biophys Acta* (1984), **773**(1): 32-38
71. Goldberg, H. J., Viegas, M. M., Margolis, B. L., Schlessinger, J., and Skorecki, K. L., The tyrosine kinase activity of the epidermal-growth-factor receptor is necessary for phospholipase A2 activation. *Biochem J* (1990), **267**(2): 461-465
72. Gordon, V. M., Klimpel, K. R., Arora, N., Henderson, M. A., and Leppla, S. H., Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. *Infect Immun* (1995), **63**(1): 82-87
73. Gorgoulis, V., Aninos, D., Priftis, C., Evagelopoulou, C., Karameris, A., Kanavaros, P., and Spandidos, D. A., Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors. *In Vivo* (1992), **6**(3): 291-296
74. Goyal, A., and Batra, J. K., Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. *Biochem J* (2000), **345 Pt 2**: 247-254
75. Green, M., and Loewenstein, P. M., Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. *Cell* (1988), **55**(6): 1179-1188
76. Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M., Kim-Sing, C., Olsson, H., Ainsworth, P., Eisen, A., Saal, H., Friedman, E., Olopade, O., Osborne, M., Weitzel, J., Lynch, H., Ghadirian, P., Lubinski, J., Sun, P., and Narod, S. A., Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. *Int J Cancer* (2005)
77. Guillemard, V., and Saragovi, H. U., Novel approaches for targeted cancer therapy. *Curr Cancer Drug Targets* (2004), **4**(4): 313-326
78. Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H. R., Upešlaciš, J., Shochat, D., Mountain, A., Flowers, D. A., and Bernstein, I., Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. *Bioconjug Chem* (2002), **13**(1): 47-58
79. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A., Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. *Clin Cancer Res* (2004), **10**(20): 7063-7070
80. Hanahan, D., Studies on transformation of *Escherichia coli* with plasmids. *J Mol Biol* (1983), **166**(4): 557-580
81. Hatakeyama, M., Tsudo, M., Minamoto, S., Kono, T., Doi, T., Miyata, T., Miyasaka, M., and Taniguchi, T., Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. *Science* (1989), **244**(4904): 551-556
82. He, D., Yang, H., Lin, Q., and Huang, H., Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells. *Int J Biochem Cell Biol* (2005), **37**(1): 192-205
83. Hebestreit, P., and Melzig, M. F., Cytotoxic activity of the seeds from *Agrostemma githago* var. *githago*. *Planta Med* (2003), **69**(10): 921-925
84. Heisler, I., Keller, J., Tauber, R., Sutherland, M., and Fuchs, H., A colorimetric assay for the quantitation of free adenine applied to determine the enzymatic activity of ribosome-inactivating proteins. *Anal Biochem* (2002), **302**(1): 114-122
85. Heisler, I., Keller, J., Tauber, R., Sutherland, M., and Fuchs, H., A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins. *Int J Cancer* (2003), **103**(2): 277-282

86. Heisler, I., Sutherland, M., Bachran, C., Hebestreit, P., Schnitger, A., Melzig, M. F., and Fuchs, H., Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells.
J Control Release (2005), **106**(1-2): 123-137
87. Hemming, A. W., Davis, N. L., Dubois, B., Quenville, N. F., and Finley, R. J., Photodynamic therapy of squamous cell carcinoma. An evaluation of a new photosensitizing agent, benzoporphyrin derivative and new photoimmunoconjugate.
Surg Oncol (1993), **2**(3): 187-196
88. Hiegemann, M., Duddeck, H., Bader, G., and Hiller, K., Structural investigation and conformational analysis of helianthoside, a saponin from *Helianthus annuus* L.
Magn Reson Chem (1995), **33**: 227-241
89. Honjo, T., Nishizuka, Y., and Hayaishi, O., Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis.
J Biol Chem (1968), **243**(12): 3553-3555
90. Huang, X., Bennett, M., and Thorpe, P. E., Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Prostate (2004), **61**(1): 1-11
91. Ippoliti, R., Lendaro, E., D'Agostino, I., Fiani, M. L., Guidarini, D., Vestri, S., Benedetti, P. A., and Brunori, M., A chimeric saporin-transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity.
Faseb J (1995), **9**(12): 1220-1225
92. Irish, J. C., and Bernstein, A., Oncogenes in head and neck cancer.
Laryngoscope (1993), **103**(1 Pt 1): 42-52
93. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., and Jain, R. K., Tumour biology: herceptin acts as an anti-angiogenic cocktail.
Nature (2002), **416**(6878): 279-280
94. Jain, R. K., Vascular and interstitial barriers to delivery of therapeutic agents in tumors.
Cancer Metastasis Rev (1990), **9**(3): 253-266
95. Jain, R. K., Delivery of molecular medicine to solid tumors.
Science (1996), **271**(5252): 1079-1080
96. Jaracz, S., Chen, J., Kuznetsova, L. V., and Ojima, I., Recent advances in tumor-targeting anticancer drug conjugates.
Bioorg Med Chem (2005), **13**(17): 5043-5054
97. Jeon, I. S., and Lee, S. M., Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus.
J Pediatr Hematol Oncol (2005), **27**(12): 681-684
98. Jiang, J. X., Chung, L. A., and London, E., Self-translocation of diphtheria toxin across model membranes.
J Biol Chem (1991), **266**(35): 24003-24010
99. Jinno, H., Ueda, M., Ozawa, S., Kikuchi, K., Ikeda, T., Enomoto, K., and Kitajima, M., Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines--a trial for less immunogenic chimeric toxin.
Cancer Chemother Pharmacol (1996), **38**(4): 303-308
100. Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., Wahl, R. L., Knox, S. J., and Vose, J. M., Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
J Clin Oncol (2001), **19**(19): 3918-3928
101. Kapp, U., Dux, A., Schell-Frederick, E., Banik, N., Hummel, M., Mucke, S., Fonatsch, C., Bullerdiek, J., Gottstein, C., Engert, A., and et al., Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice.
Ann Oncol (1994), **5 Suppl 1**: 121-126
102. Keller, J., Heisler, I., Tauber, R., and Fuchs, H., Development of a novel molecular adapter for the optimization of immunotoxins.
J Control Release (2001), **74**(1-3): 259-261
103. Keppler-Hafkemeyer, A., Brinkmann, U., and Pastan, I., Role of caspases in immunotoxin-induced apoptosis of cancer cells.
Biochemistry (1998), **37**(48): 16934-16942

104. Keppler-Hafkemeyer, A., Kreitman, R. J., and Pastan, I., Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.
Int J Cancer (2000), **87**(1): 86-94
105. Kerwin, S. M., Soy saponins and the anticancer effects of soybeans and soy-based foods.
Curr Med Chem Anti-Canc Agents (2004), **4**(3): 263-272
106. Kleinschmidt, M., Rudolph, R., and Lilie, H., Design of a modular immunotoxin connected by polyionic adapter peptides.
J Mol Biol (2003), **327**(2): 445-452
107. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S., Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
J Clin Invest (2000), **105**(8): R15-24
108. Koricanac, L. B., Todorovic, D. V., Popovic, N. M., Demajo, M. A., Ruzdijic, S. D., and Ristic-Fira, A. M., Inhibition of B16 mouse melanoma cell growth and induction of apoptotic cell death with 8-chloroadenosine-3',5'-monophosphate and tiazofurin.
Ann N Y Acad Sci (2004), **1030**: 384-392
109. Kreitman, R. J., Immunotoxins in cancer therapy.
Curr Opin Immunol (1999), **11**(5): 570-578
110. Kreitman, R. J., Recombinant toxins for the treatment of cancer.
Curr Opin Mol Ther (2003), **5**(1): 44-51
111. Kreitman, R. J., Squires, D. R., Stetler-Stevenson, M., Noel, P., FitzGerald, D. J., Wilson, W. H., and Pastan, I., Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
J Clin Oncol (2005), **23**(27): 6719-6729
112. Laemmli, U. K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature (1970), **227**(5259): 680-685
113. Langedijk, J. P., Olijhoek, T., Schut, D., Autar, R., and Meloen, R. H., New transport peptides broaden the horizon of applications for peptidic pharmaceuticals.
Mol Divers (2004), **8**(2): 101-111
114. Lear, J. D., and DeGrado, W. F., Membrane binding and conformational properties of peptides representing the NH2 terminus of influenza HA-2.
J Biol Chem (1987), **262**(14): 6500-6505
115. Leonard, W. J., Depper, J. M., Crabtree, G. R., Rudikoff, S., Pumphrey, J., Robb, R. J., Kronke, M., Svetlik, P. B., Peffer, N. J., Waldmann, T. A., and et al., Molecular cloning and expression of cDNAs for the human interleukin-2 receptor.
Nature (1984), **311**(5987): 626-631
116. Leprince, P., Noble, R. L., and Hess, G. P., Comparison of the interactions of a specific neurotoxin (alpha-bungarotoxin) with the acetylcholine receptor in *Torpedo californica* and *Electrophorus electricus* membrane preparations.
Biochemistry (1981), **20**(19): 5565-5570
117. Levavi-Sivan, B., Hedvat, R., Kanas, T., Francis, G., Becker, K., and Kerem, Z., Exposure of tilapia pituitary cells to saponins: insight into their mechanism of action.
Comp Biochem Physiol C Toxicol Pharmacol (2005), **140**(1): 79-86
118. Li, Q., Verschraegen, C. F., Mendoza, J., and Hassan, R., Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Anticancer Res (2004), **24**(3a): 1327-1335
119. Lindgren, M., Hallbrink, M., Prochiantz, A., and Langel, U., Cell-penetrating peptides.
Trends Pharmacol Sci (2000), **21**(3): 99-103
120. Liu, C., Tadayoni, B. M., Bourret, L. A., Mattocks, K. M., Derr, S. M., Widdison, W. C., Kedersha, N. L., Ariniello, P. D., Goldmacher, V. S., Lambert, J. M., Blattler, W. A., and Chari, R. V., Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
Proc Natl Acad Sci U S A (1996), **93**(16): 8618-8623
121. Liu, T. F., Cohen, K. A., Ramage, J. G., Willingham, M. C., Thorburn, A. M., and Frankel, A. E., A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells.
Cancer Res (2003), **63**(8): 1834-1837

122. Liu, T. F., Hall, P. D., Cohen, K. A., Willingham, M. C., Cai, J., Thorburn, A., and Frankel, A. E., Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
Clin Cancer Res (2005), **11**(1): 329-334
123. Lizzi, A. R., D'Alessandro, A. M., Zeolla, N., Brisdelli, F., D'Andrea, G., Pitari, G., Oratore, A., Bozzi, A., and Ippoliti, R., The effect of AZT and chloroquine on the activities of ricin and a saporin-transferrin chimeric toxin.
Biochem Pharmacol (2005), **70**(4): 560-569
124. Lundberg, M., Wikstrom, S., and Johansson, M., Cell surface adherence and endocytosis of protein transduction domains.
Mol Ther (2003), **8**(1): 143-150
125. Macrae, E. J., Giannoudis, A., Ryan, R., Brown, N. J., Hamdy, F. C., Maitland, N., and Lewis, C. E., Gene therapy for prostate cancer: Current strategies and new cell-based approaches.
Prostate (2005)
126. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T. M., Dallaire, B. K., Wey, K., Royston, I., Davis, T., and Levy, R., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Blood (1997), **90**(6): 2188-2195
127. Mangoni, M. E., Aumelas, A., Charnet, P., Roumestand, C., Chiche, L., Despau, E., Grassy, G., Calas, B., and Chavanieu, A., Change in membrane permeability induced by protegrin 1: implication of disulphide bridges for pore formation.
FEBS Lett (1996), **383**(1-2): 93-98
128. Martinon, F., and Tschopp, J., Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases.
Cell (2004), **117**(5): 561-574
129. McDonald, N., Murray-Rust, J., and Blundell, T., Structure-function relationships of growth factors and their receptors.
Br Med Bull (1989), **45**(2): 554-569
130. Melzig, M. F., Bader, G., and Loose, R., Investigations of the mechanism of membrane activity of selected triterpenoid saponins.
Planta Med (2001), **67**(1): 43-48
131. Melzig, M. F., Hebestreit, P., Gaidi, G., and Lacaille-Dubois, M. A., Structure-activity-relationship of saponins to enhance toxic effects of agrostin.
Planta Med (2005), **71**(11): 1088-1090
132. Mendelsohn, J., Targeting the epidermal growth factor receptor for cancer therapy.
J Clin Oncol (2002), **20**(18 Suppl): 1S-13S
133. Menin, L., Panchichkina, M., Keriell, C., Olivares, J., Braun, U., Seppet, E. K., and Saks, V. A., Macrocompartmentation of total creatine in cardiomyocytes revisited.
Mol Cell Biochem (2001), **220**(1-2): 149-159
134. Mishra, G., Liu, T. F., and Frankel, A. E., Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells.
Expert Opin Biol Ther (2003), **3**(7): 1173-1180
135. Mochizuki, M., Yoo, Y. C., Matsuzawa, K., Sato, K., Saiki, I., Tono-oka, S., Samukawa, K., and Azuma, I., Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng.
Biol Pharm Bull (1995), **18**(9): 1197-1202
136. Moreau, J. L., Bossus, M., de Groote, D., Francois, C., Jacques, Y., Tartar, A., and Theze, J., Characterization of a monoclonal antibody directed against the NH2 terminal area of interleukin-2 (IL-2) and inhibiting specifically the binding of IL-2 to IL-2 receptor beta chain (IL-2R beta).
Mol Immunol (1995), **32**(14-15): 1047-1056
137. Morein, B., Sundquist, B., Hoglund, S., Dalsgaard, K., and Osterhaus, A., Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.
Nature (1984), **308**(5958): 457-460
138. Morgan, D. A., Ruscetti, F. W., and Gallo, R., Selective in vitro growth of T lymphocytes from normal human bone marrows.
Science (1976), **193**(4257): 1007-1008

139. Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G., and Erlich, H., Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. 1986. *Biotechnology* (1992), **24**: 17-27
140. Naglich, J. G., Metherall, J. E., Russell, D. W., and Eidels, L., Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. *Cell* (1992), **69**(6): 1051-1061
141. Nahta, R., and Esteva, F. J., In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. *Cancer Chemother Pharmacol* (2004), **53**(2): 186-190
142. Nelson, B. H., and Willerford, D. M., Biology of the interleukin-2 receptor. *Adv Immunol* (1998), **70**: 1-81
143. Nicholson, D. W., Caspase structure, proteolytic substrates, and function during apoptotic cell death. *Cell Death Differ* (1999), **6**(11): 1028-1042
144. Nikaido, T., Shimizu, A., Ishida, N., Sabe, H., Teshigawara, K., Maeda, M., Uchiyama, T., Yodoi, J., and Honjo, T., Molecular cloning of cDNA encoding human interleukin-2 receptor. *Nature* (1984), **311**(5987): 631-635
145. Nilsson, L., and Nygard, O., Localization of the sites of ADP-ribosylation and GTP binding in the eukaryotic elongation factor EF-2. *Eur J Biochem* (1985), **148**(2): 299-304
146. Nurten, R., Ustundag, I., Sayhan, N., and Bermek, E., ADP-ribosylation of human serum proteins promoted by endogenous NAD glycohydrolase activity. *Biochem Biophys Res Commun* (1994), **200**(1): 450-458
147. Nygren, P., Fridborg, H., Csoka, K., Sundstrom, C., de la Torre, M., Kristensen, J., Bergh, J., Hagberg, H., Glimelius, B., Rastad, J., Tholander, B., and Larsson, R., Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. *Int J Cancer* (1994), **56**(5): 715-720
148. O'Hare, M., Brown, A. N., Hussain, K., Gebhardt, A., Watson, G., Roberts, L. M., Vitetta, E. S., Thorpe, P. E., and Lord, J. M., Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence. *FEBS Lett* (1990), **273**(1-2): 200-204
149. Oda, K., Matsuda, H., Murakami, T., Katayama, S., Ohgitani, T., and Yoshikawa, M., Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants. *Biol Chem* (2000), **381**(1): 67-74
150. Oess, S., and Hildt, E., Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. *Gene Ther* (2000), **7**(9): 750-758
151. Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glode, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P., and Nichols, J., Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. *J Clin Oncol* (2001), **19**(2): 376-388
152. Onda, M., Nagata, S., Tsutsumi, Y., Vincent, J. J., Wang, Q., Kreitman, R. J., Lee, B., and Pastan, I., Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. *Cancer Res* (2001), **61**(13): 5070-5077
153. Panwar, M., Kumar, M., Samarth, R., and Kumar, A., Evaluation of chemopreventive action and antimutagenic effect of the standardized Panax ginseng extract, EFLA400, in Swiss albino mice. *Phytother Res* (2005), **19**(1): 65-71
154. Passador, L., and Iglewski, W., ADP-ribosylating toxins. *Methods Enzymol* (1994), **235**: 617-631
155. Pincus, S. H., Fang, H., Wilkinson, R. A., Marcotte, T. K., Robinson, J. E., and Olson, W. C., In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. *J Immunol* (2003), **170**(4): 2236-2241

156. Plank, C., Oberhauser, B., Mechtler, K., Koch, C., and Wagner, E., The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems.
J Biol Chem (1994), **269**(17): 12918-12924
157. Plock, A., Sokolowska-Kohler, W., and Presber, W., Application of flow cytometry and microscopical methods to characterize the effect of herbal drugs on *Leishmania* Spp.
Exp Parasitol (2001), **97**(3): 141-153
158. Polito, L., Bolognesi, A., Tazzari, P. L., Farini, V., Lubelli, C., Zinzani, P. L., Ricci, F., and Stirpe, F., The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
Leukemia (2004), **18**(7): 1215-1222
159. Pop, L. M., Liu, X., Ghetie, V., and Vitetta, E. S., The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
Int Immunopharmacol (2005), **5**(7-8): 1279-1290
160. Prentice, G. A., and Merrill, A. R., An enzyme-linked immunosorbent assay for the association of the catalytic domain of diphthamide-specific ribosyltransferases to eukaryotic elongation factor-2.
Anal Biochem (1999), **272**(2): 216-223
161. Ramage, J. G., Vallera, D. A., Black, J. H., Aplan, P. D., Kees, U. R., and Frankel, A. E., The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Leuk Res (2003), **27**(1): 79-84
162. Richard, J. P., Melikov, K., Vives, E., Ramos, C., Verbeure, B., Gait, M. J., Chernomordik, L. V., and Lebleu, B., Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake.
J Biol Chem (2003), **278**(1): 585-590
163. Robb, R. J., Kutny, R. M., Panico, M., Morris, H. R., and Chowdhry, V., Amino acid sequence and post-translational modification of human interleukin 2.
Proc Natl Acad Sci U S A (1984), **81**(20): 6486-6490
164. Rojas, M., Donahue, J. P., Tan, Z., and Lin, Y. Z., Genetic engineering of proteins with cell membrane permeability.
Nat Biotechnol (1998), **16**(4): 370-375
165. Rojas, M., Yao, S., and Lin, Y. Z., Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor.
J Biol Chem (1996), **271**(44): 27456-27461
166. Romer, J. T., Kimura, H., Magdaleno, S., Sasai, K., Fuller, C., Baines, H., Connelly, M., Stewart, C. F., Gould, S., Rubin, L. L., and Curran, T., Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in *Ptc1(+/-)p53(-/-)* mice.
Cancer Cell (2004), **6**(3): 229-240
167. Rousselle, C., Clair, P., Lefauconnier, J. M., Kaczorek, M., Scherrmann, J. M., and Tamsamani, J., New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.
Mol Pharmacol (2000), **57**(4): 679-686
168. Rousselle, C., Smirnova, M., Clair, P., Lefauconnier, J. M., Chavanieu, A., Calas, B., Scherrmann, J. M., and Tamsamani, J., Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity.
J Pharmacol Exp Ther (2001), **296**(1): 124-131
169. Saltz, L. B., Meropol, N. J., Loehrer, P. J., Sr., Needle, M. N., Kopit, J., and Mayer, R. J., Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
J Clin Oncol (2004), **22**(7): 1201-1208
170. Sanger, F., Nicklen, S., and Coulson, A. R., DNA sequencing with chain-terminating inhibitors.
Proc Natl Acad Sci U S A (1977), **74**(12): 5463-5467
171. Sato, K., Mochizuki, M., Saiki, I., Yoo, Y. C., Samukawa, K., and Azuma, I., Inhibition of tumor angiogenesis and metastasis by a saponin of *Panax ginseng*, ginsenoside-Rb2.
Biol Pharm Bull (1994), **17**(5): 635-639

172. Sauve, K., Nachman, M., Spence, C., Bailon, P., Campbell, E., Tsien, W. H., Kondas, J. A., Hakimi, J., and Ju, G., Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. *Proc Natl Acad Sci U S A* (1991), **88**(11): 4636-4640
173. Schnell, R., Staak, O., Borchmann, P., Schwartz, C., Matthey, B., Hansen, H., Schindler, J., Ghetie, V., Vitetta, E. S., Diehl, V., and Engert, A., A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. *Clin Cancer Res* (2002), **8**(6): 1779-1786
174. Schwarze, S. R., Ho, A., Vocero-Akbani, A., and Dowdy, S. F., In vivo protein transduction: delivery of a biologically active protein into the mouse. *Science* (1999), **285**(5433): 1569-1572
175. Schwarze, S. R., Hruska, K. A., and Dowdy, S. F., Protein transduction: unrestricted delivery into all cells? *Trends Cell Biol* (2000), **10**(7): 290-295
176. Seeman, P., Cheng, D., and Iles, G. H., Structure of membrane holes in osmotic and saponin hemolysis. *J Cell Biol* (1973), **56**(2): 519-527
177. Segal, R., Shatkovsky, P., and Milo-Goldzweig, I., On the mechanism of saponin hemolysis--I. Hydrolysis of the glycosidic bond. *Biochem Pharmacol* (1974), **23**(5): 973-981
178. Shaw, J. P., Akiyoshi, D. E., Arrigo, D. A., Rhoad, A. E., Sullivan, B., Thomas, J., Genbauffe, F. S., Bacha, P., and Nichols, J. C., Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. *J Biol Chem* (1991), **266**(31): 21118-21124
179. Shibata, S., Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. *J Korean Med Sci* (2001), **16 Suppl**: S28-37
180. Shillitoe, E. J., and Pellenz, C., Factors that limit the effectiveness of herpes simplex virus type 1 for treatment of oral cancer in mice. *Clin Cancer Res* (2005), **11**(8): 3109-3116
181. Shinagawa, K., Imajo, K., Tada, S., Tsubota, T., and Kimura, I., Overexpression of interleukin-2 receptor alpha mRNA in pulmonary lymphocytes of lung cancer patients associated with interstitial pulmonary shadow. *Acta Med Okayama* (1993), **47**(2): 73-78
182. Siegel, J. P., Sharon, M., Smith, P. L., and Leonard, W. J., The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. *Science* (1987), **238**(4823): 75-78
183. Silhol, M., Tyagi, M., Giacca, M., Lebleu, B., and Vives, E., Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. *Eur J Biochem* (2002), **269**(2): 494-501
184. Silverman, J. A., Mindell, J. A., Zhan, H., Finkelstein, A., and Collier, R. J., Structure-function relationships in diphtheria toxin channels: I. Determining a minimal channel-forming domain. *J Membr Biol* (1994), **137**(1): 17-28
185. Singh, B., Bhat, T. K., and Singh, B., Potential therapeutic applications of some antinutritional plant secondary metabolites. *J Agric Food Chem* (2003), **51**(19): 5579-5597
186. Sjolander, A., and Cox, J. C., Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. *Adv Drug Deliv Rev* (1998), **34**(2-3): 321-338
187. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* (2001), **344**(11): 783-792
188. Smallshaw, J. E., Ghetie, V., Rizo, J., Fulmer, J. R., Trahan, L. L., Ghetie, M. A., and Vitetta, E. S., Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. *Nat Biotechnol* (2003), **21**(4): 387-391

189. Smith, K. A., Interleukin-2: inception, impact, and implications.
Science (1988), **240**(4856): 1169-1176
190. Snyder, E. L., and Dowdy, S. F., Cell penetrating peptides in drug delivery.
Pharm Res (2004), **21**(3): 389-393
191. Soler-Rodriguez, A. M., Ghetie, M. A., Oppenheimer-Marks, N., Uhr, J. W., and Vitetta, E. S., Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.
Exp Cell Res (1993), **206**(2): 227-234
192. Soltysik, S., Wu, J. Y., Recchia, J., Wheeler, D. A., Newman, M. J., Coughlin, R. T., and Kensil, C. R., Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function.
Vaccine (1995), **13**(15): 1403-1410
193. Sparg, S. G., Light, M. E., and van Staden, J., Biological activities and distribution of plant saponins.
J Ethnopharmacol (2004), **94**(2-3): 219-243
194. Steinberg, D. A., Hurst, M. A., Fujii, C. A., Kung, A. H., Ho, J. F., Cheng, F. C., Loury, D. J., and Fiddes, J. C., Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity.
Antimicrob Agents Chemother (1997), **41**(8): 1738-1742
195. Stirpe, F., Bailey, S., Miller, S. P., and Bodley, J. W., Modification of ribosomal RNA by ribosome-inactivating proteins from plants.
Nucleic Acids Res (1988), **16**(4): 1349-1357
196. Stortelers, C., Souriau, C., van Liempt, E., van de Poll, M. L., and van Zoelen, E. J., Role of the N-terminus of epidermal growth factor in ErbB-2/ErbB-3 binding studied by phage display.
Biochemistry (2002), **41**(27): 8732-8741
197. Sutherland, M., Keller, J., Heisler, I., Tauber, R., and Fuchs, H., A novel molecular adapter for the site-specific trapping of immunotoxins - is it functional?
Clin Chem Lab (2001), **39**(A76)
198. Sweeney, E. B., and Murphy, J. R., Diphtheria toxin-based receptor-specific chimaeric toxins as targeted therapies.
Essays Biochem (1995), **30**: 119-131
199. Takeshita, T., Asao, H., Ohtani, K., Ishii, N., Kumaki, S., Tanaka, N., Munakata, H., Nakamura, M., and Sugamura, K., Cloning of the gamma chain of the human IL-2 receptor.
Science (1992), **257**(5068): 379-382
200. Talpur, R., Apisarnthanarax, N., Ward, S., and Duvic, M., Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).
Leuk Lymphoma (2002), **43**(1): 121-126
201. Tian, F., Zhang, X., Tong, Y., Yi, Y., Zhang, S., Li, L., Sun, P., Lin, L., and Ding, J., PE, a New Sulfated Saponin from Sea Cucumber, Exhibits Anti-Angiogenic and Anti-Tumor Activities in vitro and In Vivo.
Cancer Biol Ther (2005), **4**(8): 874-882
202. Torchilin, V. P., Levchenko, T. S., Rammohan, R., Volodina, N., Papahadjopoulos-Sternberg, B., and D'Souza, G. G., Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes.
Proc Natl Acad Sci U S A (2003), **100**(4): 1972-1977
203. Torchilin, V. P., Rammohan, R., Weissig, V., and Levchenko, T. S., TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors.
Proc Natl Acad Sci U S A (2001), **98**(15): 8786-8791
204. Trehin, R., Krauss, U., Muff, R., Meinecke, M., Beck-Sickinger, A. G., and Merkle, H. P., Cellular internalization of human calcitonin derived peptides in MDCK monolayers: a comparative study with Tat(47-57) and penetratin(43-58).
Pharm Res (2004), **21**(1): 33-42
205. Uchiyama, T., Wano, Y., Tsudo, M., Umadome, H., Hori, T., Tamori, S., Uchino, H., Yodoi, J., Maeda, M., Kobayashi, N., and et al., Abnormal expression of interleukin-2 receptor (Tac antigen) in adult T-cell leukemia.
Princess Takamatsu Symp (1984), **15**: 253-258

206. Vago, R., Marsden, C. J., Lord, J. M., Ippoliti, R., Flavell, D. J., Flavell, S. U., Ceriotti, A., and Fabbrini, M. S., Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells. *Febs J* (2005), **272**(19): 4983-4995
207. Vallera, D. A., Jin, N., Baldrice, J. M., Panoskaltis-Mortari, A., Chen, S. Y., and Blazar, B. R., Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. *Cancer Res* (2000), **60**(4): 976-984
208. Vallera, D. A., Todhunter, D. A., Kuroki, D. W., Shu, Y., Sicheneder, A., and Chen, H., A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. *Clin Cancer Res* (2005), **11**(10): 3879-3888
209. Van Ness, B. G., Howard, J. B., and Bodley, J. W., ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. *J Biol Chem* (1980), **255**(22): 10717-10720
210. Van Ness, B. G., Howard, J. B., and Bodley, J. W., ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products. *J Biol Chem* (1980), **255**(22): 10710-10716
211. vanderSpek, J., Cassidy, D., Genbauffe, F., Huynh, P. D., and Murphy, J. R., An intact transmembrane helix 9 is essential for the efficient delivery of the diphtheria toxin catalytic domain to the cytosol of target cells. *J Biol Chem* (1994), **269**(34): 21455-21459
212. vanderSpek, J. C., Mindell, J. A., Finkelstein, A., and Murphy, J. R., Structure/function analysis of the transmembrane domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells. *J Biol Chem* (1993), **268**(16): 12077-12082
213. Vives, E., Present and future of cell-penetrating peptide mediated delivery systems: "Is the Trojan horse too wild to go only to Troy?" *J Control Release* (2005), **109**(1-3): 77-85
214. Vives, E., Brodin, P., and Lebleu, B., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. *J Biol Chem* (1997), **272**(25): 16010-16017
215. Vocero-Akbani, A. M., Heyden, N. V., Lissy, N. A., Ratner, L., and Dowdy, S. F., Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. *Nat Med* (1999), **5**(1): 29-33
216. Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., and Kaminski, M. S., Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. *J Clin Oncol* (2000), **18**(6): 1316-1323
217. Voss, S. D., Leary, T. P., Sondel, P. M., and Robb, R. J., Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain. *Proc Natl Acad Sci U S A* (1993), **90**(6): 2428-2432
218. Wagner, E., Plank, C., Zatloukal, K., Cotten, M., and Birnstiel, M. L., Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. *Proc Natl Acad Sci U S A* (1992), **89**(17): 7934-7938
219. Wahl, A. F., Donaldson, K. L., Mixan, B. J., Trail, P. A., and Siegall, C. B., Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. *Int J Cancer* (2001), **93**(4): 590-600
220. Weishaupt, K. R., Gomer, C. J., and Dougherty, T. J., Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. *Cancer Res* (1976), **36**(7 PT 1): 2326-2329

221. Wiley, R. G., and Kline, I. R., Neuronal lesioning with axonally transported toxins. *J Neurosci Methods* (2000), **103**(1): 73-82
222. Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T. B., and Murphy, J. R., Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. *Protein Eng* (1987), **1**(6): 493-498
223. Williams, D. P., Snider, C. E., Strom, T. B., and Murphy, J. R., Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. *J Biol Chem* (1990), **265**(20): 11885-11889
224. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., and White, C. A., Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. *J Clin Oncol* (2002), **20**(15): 3262-3269
225. Woldemichael, G. M., and Wink, M., Identification and biological activities of triterpenoid saponins from *Chenopodium quinoa*. *J Agric Food Chem* (2001), **49**(5): 2327-2332
226. Wu, R. T., Chiang, H. C., Fu, W. C., Chien, K. Y., Chung, Y. M., and Horng, L. Y., Formosanin-C, an immunomodulator with antitumor activity. *Int J Immunopharmacol* (1990), **12**(7): 777-786
227. Yamaizumi, M., Mekada, E., Uchida, T., and Okada, Y., One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. *Cell* (1978), **15**(1): 245-250
228. Yamasaki, Y., Ito, K., Enomoto, Y., and Sutko, J. L., Alterations by saponins of passive Ca²⁺ permeability and Na⁺-Ca²⁺ exchange activity of canine cardiac sarcolemmal vesicles. *Biochim Biophys Acta* (1987), **897**(3): 481-487
229. Yarden, Y., Biology of HER2 and its importance in breast cancer. *Oncology* (2001), **61 Suppl 2**: 1-13
230. Yarden, Y., The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. *Eur J Cancer* (2001), **37 Suppl 4**: S3-8
231. Zav'yalov, V. P., Navolotskaya, E. V., Isaev, I. S., Kaurov, O. A., Kolobov, A. A., Vasilenko, R. N., Galaktionov, V. G., and Denesyuk, A. I., Nonapeptide corresponding to the sequence 27-35 of the mature human IL-2 efficiently competes with rIL-2 for binding to thymocyte receptors [corrected]. *Immunol Lett* (1992), **31**(3): 285-288
232. Zhang, J., Use of biotinylated NAD to label and purify ADP-ribosylated proteins. *Methods Enzymol* (1997), **280**: 255-265
233. Zhou, J., Bai, Y., and Weiner, H., Proteolysis prevents in vivo chimeric fusion protein import into yeast mitochondria. Cytosolic cleavage and subcellular distribution. *J Biol Chem* (1995), **270**(28): 16689-16693